Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer
Bristol Myers Squibb
Leading for the Future of Patient Care
Adam Lenkowsky has dedicated his career to advancing patient care, expanding the boundaries of science to improve the lives of patients across the globe. In his 27 years at Bristol Myers Squibb, Adam has played a critical role in the company’s evolution, accelerating the impact of its first-in-class medicines and patient- centric culture.
He began his BMS career as a sales representative and worked his way up to Executive Vice President, Chief Commercialization Officer. Adam has seen the industry undergo several transformations. His consistent ability to harness innovation, technology, and talent has enabled him to navigate these transformations over time to positively impact the business.
Under Adam’s leadership, BMS expanded its portfolio through the acquisitions of Mirati Therapeutics, RayzeBio, and Karuna Therapeutics. The acquisitions complement BMS’s existing oncology portfolio, add a differentiated and innovative platform to an increasingly diversified oncology portfolio, and accelerate the expansion and diversification of BMS’s neuroscience portfolio.
In addition, Adam adds value to the company’s commercialization model, which positions BMS for future growth as it transforms from 10 new product launches over the last five years to a company with potentially more than 15 by the end of the decade.
As a champion of inclusion and diversity, Adam works to meaningfully realize the company’s vision: to transform patients’ lives through science. His approach to Commercialization leadership is rooted in BMS’s long-standing commitment to inclusion and diversity. Every day, he helps advance the company’s priorities to drive scientific innovation, demonstrate BMS’s Value of Inclusion, and transform industry practices and policies to achieve equitable advancement and outcomes for all.
Adam helps his teams reimagine commercialization and evolve the way BMS delivers its products to reach more patients around the world faster. With a relentless focus on the patients he serves every day, Adam continues to drive BMS’s growth forward while navigating the dynamic challenges facing the biopharmaceutical industry today. His outstanding achievements reflect his commitment to BMS’s mission, his passion to help others, and his motivation.
